Nationwide Recall Issued for ADHD Medication Due to Ineffectiveness
A nationwide recall has been issued for a widely used ADHD medication due to concerns over its effectiveness. The Food and Drug Administration (FDA) announced the recall of several lots of lisdexamfetamine dimesylate capsules, a generic version of Vyvanse, on October 28.
Issues with the Medication
The Board of Pharmacy reported that these capsules failed essential dissolution tests. Proper dissolution is critical for drugs to be properly absorbed by the body and to exert their intended effects. The recalled lot may not deliver adequate medication levels, which can significantly affect its therapeutic efficacy.
Safety Information
Despite the ineffectiveness of the recalled medication, officials have confirmed that there are no safety or health risks associated with taking it. Patients are encouraged to act promptly if they possess the affected capsules.
Dosage Details and Affected Batches
The recall includes various dosage strengths of the medication, specifically:
- 10 mg
- 20 mg
- 30 mg
- 40 mg
- 50 mg
- 60 mg
- 70 mg
Sun Pharmaceutical Industries, Inc. distributed the recalled medication between May 1, 2024, and November 13, 2024. Notably, these capsules remain valid until their expiration date in 2026.
Next Steps for Patients
Patients who have received these medications should contact their healthcare provider or pharmacy. They can obtain replacements or refunds for the impacted products.
